INCY Forecast



Bearish<—>Bullish



80% Confidence




Bullish Case: Recent Zynyz FDA approval enhances pipeline optimism, coupled with potential Opzelura expansion boosting revenues.




Bearish Case: High operational costs, market competition, and Jakafi patent expiration in 2028 pose significant revenue risks.




Potential Outcomes:
  • Opzelura growth continues: 60% chance.
  • Competitive pressures hinder profits: 25% chance.
  • Pipeline approval delays: 15% chance.



May 20, 2025


Incyte Forecast

INCY        Incyte











Correlated Assets

Assets that tend to move strongly with INCY



PNC Forecast + Options Trading Strategies   PNC  PNC Financial Services (0.89)


FITB Forecast + Options Trading Strategies   FITB  Fifth Third Bancorp (0.86)


KKR Forecast + Options Trading Strategies   KKR  KKR (0.85)


MAC Forecast + Options Trading Strategies   MAC  Macerich (0.84)


MTB Forecast + Options Trading Strategies   MTB  M & T (0.83)



Uncorrelated Assets

Assets with little price relationship to INCY



AAP Forecast + Options Trading Strategies   AAP  Advance Auto Parts (-0.0)


FE Forecast + Options Trading Strategies   FE  Firstenergy (0.0)


ENS Forecast + Options Trading Strategies   ENS  Enersys (0.01)


NKE Forecast + Options Trading Strategies   NKE  Nike (0.01)


BAX Forecast + Options Trading Strategies   BAX  Baxter International (0.01)



Anticorrelated Assets

Assets that tend to move strongly against INCY



WBA Forecast + Options Trading Strategies   WBA  Walgreens Boots Alliance (-0.47)


VOD Forecast + Options Trading Strategies   VOD  Vodafone (-0.48)


XP Forecast + Options Trading Strategies   XP  XP (-0.48)


EWW Forecast + Options Trading Strategies   EWW  iShares MSCI Mexico (-0.68)


UDN Forecast + Options Trading Strategies   UDN  Invesco DB US Dollar Index Bearish (-0.74)









Become a more profitable investor with AI optimized trading strategies






×

Chat with INCY


 Ask any question about INCY!